2141-17-5

Basic information

• Product Name: 4-Hydroxy-Testosterone
• Synonyms: (8R,9S,10R,13S,14S,17S)-4,17-dihydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one;4,17 beta-dihydroxy-4-androstene-3-one;(17β)-4,17-Dihydroxyandrost-4-en-3-one
• CAS NO: 2141-17-5
• Molecular Formula: C₁₉H₂₈O₃
• Molecular Weight: 304.423820
• Product Categories: Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Steroids
• Mol File: 2141-17-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 222-223 °C
• Boiling Point: 476.3 °C at 760 mmHg
• Flash Point: 255.9 °C
• Appearance: /
• Density: 1.19 g/cm³
• Vapor Pressure: 4.52E-11mmHg at 25°C
• Refractive Index: 1.578
• PKA: 9.32±0.70(Predicted)
• CAS DataBase Reference: 4-Hydroxy-Testosterone(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Hydroxy-Testosterone(2141-17-5)
• EPA Substance Registry System: 4-Hydroxy-Testosterone(2141-17-5)

Safety Data

• Hazardous Substances Data: 2141-17-5(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

4-Hydroxytestosterone is an anabolic steroid and does not have any therapeutic indication. 4-Hydroxytestosterone is metabolite of the aromatase inhibitor Formestane (F692250). 4-Hydroxytestosterone co ncentration in the urine can be used as a biomarker for steroid misuse. Controlled Substance.

InChI:InChI=1/C19H28O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,16,21-22H,3-10H2,1-2H3/t11-,12-,13-,16-,18+,19-/m0/s1

Upstream product

• 13452-06-7 4-hydroxy-3-oxo-4-androsten-17β-yl acetate 
• 855-19-6 clostebol acetate 
• 4721-70-4 4,17β-dihydroxy-4,6-androstadien-3-one 
• 2189-83-5 17β-hydroxy-4β,5-epoxy-5β-androstan-3-one 
• 17597-25-0 17β-hydroxy-4α,5-epoxy-5α-androstan-3-one 
• 1045-69-8 testosterone acetate 
• 58-22-0 testosterone 
• 571-22-2 5β-androstan-17β-ol-3-one 
• 51154-10-0 17β-hydroxy-4ξ,5-oxido-5ξ-androstan-3-one 
• 7637-07-2 boron trifluoride 
• 71-43-2 benzene 
• 2189-83-5 (10R,13S,17S)-17-Hydroxy-10,13-dimethyl-tetradecahydro-20-oxa-cyclopropa[4,5]cyclopenta[a]phenanthren-3-one 

Downstream Products

• 1290088-67-3 17β-acetoxy-4-oxo-5α-androstano[2,3-d]isoxazole 
• 1290088-68-4 2-cyano-3,17β-dihydroxy-5α-androst-2-en-4-one 
• 171063-41-5 17β-hydroxy-4-oxo-5α-androstano[2,3-d]pyrazole 
• 1202643-15-9 C₂₈H₅₂O₃Si₃ 
• 104921-27-9 17β-hydroxy-5β,17α-pregn-20-yno<3,4-c>-1',2',5'-oxadiazole 
• 104921-26-8 17β-hydroxy-5α,17α-pregn-20-yno<3,4-c>-1',2',5'-oxadiazole 
• 112517-11-0 5α-androstano<3,4-c>-1',2',5'-oxadiazol-17β-ol 
• 112517-10-9 5β-androstano<3,4-c>-1',2',5'-oxadiazol-17β-ol 
• 104921-30-4 5α-androstano<3,4-c>-1',2',5'-oxadiazol-17-one 
• 104921-31-5 5β-androstano<3,4-c>-1',2',5'-oxadiazol-17-one 
• 38553-32-1 (8R,9S,10R,13S,14S,17S)-17-(Cyclopent-1-enyloxy)-4-hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one 
• 112573-62-3 3,4-dioximino-5ξ-androstan-17β-ol 
• 103270-11-7 4,17β-bis-phenylacetoxy-androst-4-en-3-one 
• 2562-44-9 17β-(3-cyclopentyl-propionyloxy)-4-hydroxy-androst-4-en-3-one 

Relevant articles and documents

-

-

C-19 steroids for cosmetic uses

The present invention relates to novel uses of C-19 steroid compounds, in particular C-19 steroids having an androsten-17-(OR 4 )-3-one structure for cosmetic and further uses, wherein R 4 is hydrogen or an unsubstituted or substituted alkyl, aryl, acyl or any group leading to hydroxyl upon biological metabolization or chemical deprotection. The present invention particularly relates to selected C-19 steroids displaying properties of high binding affinity to androgen receptor to block dihydotestosterone from binding, while at the same time providing anabolic effects, which is useful for certain applications, particularly for influencing or controlling problems of the skin and its skin-associated body structures like cellulite, wrinkles, adipose fat tissues, hair follikles or hair growth; for influencing or controlling gland function and activity such as the sebaceous gland and other glands affecting the skin and/or perspiration. The present invention also describes a composition comprising a combination of such a compound and dimethyl isosorbide.

Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers

The present invention relates to novel uses of 4,17β-dihydroxyandrost-4-ene-3-one (hereinafter 4-hydroxytestosterone), to a process for their preparation, to pharmaceutical compositions containing them, and to the use of said compounds for the prophylaxis and/or treatment of hormone-dependent or hormone receptor regulated cancers in mammals.